Thompson Siegel & Walmsley LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Thompson Siegel & Walmsley LLC boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,059 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,626 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in ANI Pharmaceuticals were worth $7,899,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its position in ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the last quarter. UBS Group AG raised its stake in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the period. Geode Capital Management LLC raised its stake in shares of ANI Pharmaceuticals by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock valued at $37,682,000 after buying an additional 19,258 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $32,992,000. Finally, Rubric Capital Management LP raised its stake in shares of ANI Pharmaceuticals by 33.3% in the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock valued at $31,457,000 after buying an additional 85,745 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00. Following the sale, the vice president directly owned 78,390 shares in the company, valued at approximately $6,126,962.40. The trade was a 0.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 2,772 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total value of $220,374.00. Following the sale, the senior vice president owned 78,696 shares in the company, valued at approximately $6,256,332. The trade was a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 88,950 shares of company stock worth $6,900,618 in the last 90 days. 8.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $76.71 on Tuesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 52-week low of $58.70 and a 52-week high of $99.50. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of 19.42 and a beta of 0.44. The business’s fifty day moving average is $78.77 and its 200 day moving average is $79.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the previous year, the company posted $1.70 EPS. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 7.96 EPS for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the topic of several research reports. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.